OpenAI has agreed to acquire Astral, a startup behind widely used Python development tools, in a deal designed to sharpen its Codex coding assistant as competition with Anthropic intensifies. The ...

With Gemini and a simple Python script, I rebuilt YouTube email alerts. Now I won't miss another comment. Here's how you can do the same.

UC San Diego cognitive scientist Philip Guo created Python Tutor, a free tool that makes code “visible” step by step. The research behind it earned a Test of Time award, recog ...

This udemy python course aims to get you up to speed, covering everything from the very beginning. We’re talking about setting it up on your computer, figuring out how data works in Python, and all ...

The MarketWatch News Department was not involved in the creation of this content.-- Aible launches SafeClaw that enables long-running agents with built-in enterprise AI governance ...

Learn how to automate your Git workflow and environment variables into a single, error-proof command that handles the boring ...

Python’s Kiss” is a highly anticipated collection of 13 stories by Louise Erdrich, illustrated with artwork by Erdrich’s ...

In the era of A.I. agents, many Silicon Valley programmers are now barely programming. Instead, what they’re doing is deeply, ...

JetBrains, the company behind the popular PyCharm IDE, offers a free introductory Python course. This is a pretty neat option if you like learning by doing, especially within a professional coding ...

Federal Communications Commission Chair Brendan Carr is urging broadcast media companies to air “patriotic, pro-America content” in a new campaign aligned with President Donald Trump’s Freedom 250 ...

BP has suspended its share buyback program and increased its cost-cutting goal by $1.5 billion to bolster its balance sheet and increase investment in oil production. The company's current struggles ...

Amgen has terminated its rocatinlimab collaboration with Kyowa Kirin, walking away from the anti-OX40 antibody five years after paying $400 million for rights to the autoimmune disease drug candidate.